OBJECTIVES: To determine the efficacy of desmopressin acetate in preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders.
SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coaguopathies Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant and abstract books of conferences proceedings. We also searched for any randomised controlled trials in a registry of ongoing trials and the reference lists of relevant articles and reviews.Date of most recent search: 18 June 2015.
SELECTION CRITERIA: Randomised and quasi-randomised controlled trials investigating the efficacy of desmopressin acetate versus tranexamic acid or factor VIII or rFactor VII or fresh frozen plasma in preventing and treating congenital bleeding disorders during pregnancy were eligible.
DATA COLLECTION AND ANALYSIS: No trials matching the selection criteria were eligible for inclusion.
MAIN RESULTS: No trials matching the selection criteria were eligible for inclusion.
AUTHORS' CONCLUSIONS: The review did not identify any randomised controlled trials investigating the relative effectiveness of desmopressin acetate for bleeding during pregnancy in women with congenital bleeding disorders. In the absence of high quality evidence, clinicians need to use their clinical judgement and lower level evidence (e.g. from observational trials) to decide whether or not to treat women with congenital bleeding disorders with desmopressin acetate.Given the ethical considerations, future randomised controlled trials are unlikely. However, other high quality controlled studies (such as risk allocation designs, sequential design, parallel cohort design) to investigate the risks and benefits of using desmopressin acetate in this population are needed.
OBJECTIVES: To evaluate the efficacy and safety of DDAVP in preventing and treating acute bleeding in pregnant women with bleeding disorders.
SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coaguopathies Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant and abstract books of conferences proceedings. We also searched several clinical trial registries and grey literature (27 August 2017).Date of most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coaguopathies Trials Register: 01 October 2018.
SELECTION CRITERIA: Randomised and quasi-randomised controlled trials investigating the efficacy of DDAVP versus tranexamic acid or factor VIII or rFactor VII or fresh frozen plasma in preventing and treating congenital bleeding disorders during pregnancy were eligible.
DATA COLLECTION AND ANALYSIS: No trials matching the selection criteria were eligible for inclusion.
MAIN RESULTS: No trials matching the selection criteria were eligible for inclusion.
AUTHORS' CONCLUSIONS: No randomised controlled trials were identified investigating the relative effectiveness of DDAVP for bleeding during pregnancy in women with congenital bleeding disorders. In the absence of high-quality evidence, clinicians need to use their clinical judgement and lower level evidence (e.g. from observational trials) to decide whether or not to treat women with congenital bleeding disorders with DDAVP.Given the ethical considerations, future randomised controlled trials are unlikely. However, other high-quality controlled studies (such as risk allocation designs, sequential design, parallel cohort design) to investigate the risks and benefits of using DDAVP in this population are needed.Given that there are unlikely to be any trials published in this area, this review will no longer be regularly updated.
METHODS: L-arginine (2 % w/v.) was added to five commercial fancy waters: Oasis-Lemon, Oasis-Lemon Mint, Perrier-Lemon, Perrier-Grapefruit, Pellegrino-Lemon; and deionized water served as a negative control. The pH, buffer capacity of added Arg, and F- concentrations were measured. Tooth specimens were prepared and baseline volumetric assessment (T0) was conducted using micro-CT. Subsequently, the specimens were immersed in fancy waters for 72 h, kept in an incubator (37 ℃) and solutions were changed every 24 h. After the experimental cycle (T1), 3D volumetric analysis was performed, and 3D structural images were reconstructed for qualitative assessment.
RESULTS: The pH and F- concentrations of fancy waters with Arg were significantly higher than the control (p < 0.001). The buffer capacity of added Arg with Perrier-Grapefruit was significantly higher than Oasis-Lemon, Oasis-Lemon Mint & Pellegrino-Lemon (p < 0.05), except for Perrier-Lemon (p > 0.05). At T1, the specimen volume in Oasis-Lemon Mint (+/- Arg) and Pellegrino-Lemon (control) was significantly lower than T0 (p < 0.05). At T1, the specimen volume of Oasis-Lemon Mint and Pellegrino-Lemon (control) was significantly lower than Arg-containing fancy waters (p < 0.05). Surface contrast indicating wear was evident from T0 to T1 in specimens from the Oasis-Lemon Mint (+/- Arg) and Pellegrino-Lemon (- Arg).
CONCLUSION: Incorporating Arg in fancy waters reduces the potential of erosive tooth wear associated with these beverages.
CLINICAL SIGNIFICANCE: Consuming fancy water beverages (flavoured sparkling/carbonated) can lead to erosive tooth wear in young people. Incorporating Arg in fancy water beverages can prevent the erosive wear potential of these beverages while alleviating the burden of oral care on individuals at risk to erosive wear.
Subjects and Methods: Two groups of 40 patients each having dentinal hypersensitivity were treated using 8% proarginine and iontophoresis. The patients were recalled after 1, 2, and 4 weeks. The scores were tabulated and the results were analyzed using SPSS statistical software.
Results: Visual analog scale between the two groups showed a significant difference from the 1st week till the 4th week. ANOVA values showed the reduction in the dentinal hypersensitivity in Group 2 using the iontophoresis along with the 8.0% arginine-calcium carbonate toothpaste. The Cochran-Mantel-Haenszel correlation test of the Schiff's dentinal hypersensitivity cross-tabulation showed P < 0.001 which was statistically significant reduction after the 4th week following the application of 8.0% arginine-calcium carbonate along with iontophoresis.
Conclusion: Iontophoresis, when used along with Colgate® Sensitive Pro-Relief™ toothpaste, can provide additional benefit as this provides a better sealing effect.